医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Huami Corp to Host Investor Fireside Chat with CEO Wang Huang on July 21

2020年07月09日 AM12:55
このエントリーをはてなブックマークに追加


 

CUPERTINO, Calif. & BEIJING

Huami Corp. and Huami-USA (NYSE: HMI) today announced that it will hold a Fireside Chat conference call for investors on Tuesday, July 21, 2020. The company will discuss its strategy and provide an operational update. Speakers will include Chairman, CEO and founder, Wang Huang; CFO David Cui; and COO Mike Yeung.

The call will begin at 10:00 a.m. EDT U.S. / 10:00 p.m. China Standard Time.

Participants can access the call by dialing +1-888-346-8982, or +1-412-902-4272 for international callers, and ask to be connected to the call for “Huami Corporation”.

A free, live webcast of the conference call will be available on the Investors section of the company’s website at https://www.huami.com/investor. A replay will be archived on the site.

About Huami Corporation (NYSE:HMI)

Huami’s mission is to connect health with technology. Since its inception in 2013, Huami has developed a platform of proprietary technology including AI chips, biometric sensors, and data algorithms, which drive a broadening line of smart health devices for consumers, and analytics services for industry. In 2019, Huami shipped 42.3 million units of smart wearable devices, including its own Amazfit brand, and products developed and manufactured for Xiaomi and Timex, comprising 26% of global category shipments1. Huami Corp is based in Hefei, China, with U.S. operations, Huami-USA, based in Cupertino, Calif.

For more information, please visit https://www.huami.com/investor/pages/company-profile

1 IDC, Correcting and Replacing Shipments of Wearable Devices, 3/10/20

View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005721/en/

CONTACT

For media inquiries:

lydia.huang@huami-usa.com, c: 407-800-5625

For investors:

brad.samson@huami-usa.com, c: 714-955-3951

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates